AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00837785
Drug: BG00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg (two 120 mg capsules) orally three times a day
Trial: NCT00837785
Drug: BG00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg (two 120 mg capsules) orally twice a day
Trial: NCT04229901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as an intravenous (IV) infusion
Trial: NCT01215279
Drug: AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral treatment once daily for 28 days
Trial: NCT01215279
Drug: Placebo to AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment once daily for 28 days
Trial: NCT00835484
Drug: OMNICEF® 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 300 mg, single-dose fasting
Trial: NCT02799069
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
Trial: NCT02627820
Drug: Isis 420915/GSK 299872
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label study in comparison to historic control.
Trial: NCT00301340
Drug: 5% Lice Asphyxiator lotion - Summers Laboratories, Inc.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01471353
Drug: Sorafenib Plus Capecitabine (SorCape)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
Trial: NCT00357500
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00357500
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04651036
Drug: QL0605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a pegfilgrastim biosimilar to US Neulasta.
Trial: NCT04651036
Drug: US Neulasta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US Neulasta
Trial: NCT01022983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ml/kg/hours - same infusion rate as active comparator
Trial: NCT02555735
Drug: Standard of Care Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's Choice Chemotherapy Treatment (non-guided)
Trial: NCT00630955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once per day for 7 days
Trial: NCT00756873
Drug: Administration of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo qd orally day 0-14
Trial: NCT00756873
Drug: Administration of etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg qd orally day 0-14
Trial: NCT00756873
Drug: Administration of etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
Trial: NCT03333551
Drug: F18 Florbetapir (amyvid) cardiac PET/CT imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
Trial: NCT03123094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT02057679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
Trial: NCT03981770
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
Trial: NCT03804697
Drug: selective anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
Trial: NCT00736658
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral admin. of doses at 11 days through a 12 days period.
Trial: NCT00736658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral admin. of doses at 11 days through a 12 days period.
Trial: NCT03351296
Drug: LV5FU2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
Trial: NCT03351296
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 750 mg/m² twice daily, days 1-14
Trial: NCT02084654
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04762784
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
Trial: NCT00136799
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02730533
Drug: No PPI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No PPI treatment before ESD procedure
Trial: NCT01814904
Drug: colestilan-M
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSAeq 6 g/day
Trial: NCT00730132
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
Trial: NCT02241551
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles in the mFOLFIRINOX
Trial: NCT01585623
Drug: SAR302503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Trial: NCT00440167
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)
Trial: NCT01694212
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03911037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
Trial: NCT01131637
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
Trial: NCT00908128
Drug: CellCept®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CellCept® Tablets, 500 mg
Trial: NCT01596998
Drug: Levobupivacaine with epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
Trial: NCT03155503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT04089553
Drug: AZD4635
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
Trial: NCT00663481
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02330237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000330
Drug: Opioid-Related Disorders
RxNorm normalized name: DRUGS FOR ACID RELATED DISORDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03317444
Drug: TRC101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT03317444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT03058614
Drug: CEUS
RxNorm normalized name: COPRINUS MICACEUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
Trial: NCT03069183
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
Trial: NCT04050410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill given as 1 dose
Trial: NCT00005571
Drug: h5G1.1-mAb
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02554877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT02478775
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
Trial: NCT01529632
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
Trial: NCT01529632
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
Trial: NCT01529632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
Trial: NCT01004705
Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
Trial: NCT01004705
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A once daily oral dose of simvastatin for 12 weeks.
Trial: NCT02476045
Drug: 5-fluorouracil,leucovorin,panitumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment (ARM A)
Trial: NCT02476045
Drug: Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment
Trial: NCT00835666
Drug: PROSCAR®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 5 mg, single dose fasting
Trial: NCT00729976
Drug: Ibuprofen suppository
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-10mg/Kg of ibuprofen
Trial: NCT00729976
Drug: Ibuprofen Suspension
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-10mg/Kg
Trial: NCT01148277
Drug: midazolam and fentanyl
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
Trial: NCT01148277
Drug: midazolam anf fentanyl
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
Trial: NCT00131118
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00820690
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 cycles AC: doxorubicin 60mg/m2
Trial: NCT00820690
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 cycles AC: cyclophosphamide 600mg/m2
Trial: NCT00654680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00012311
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00012311
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00012311
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04397094
Drug: Theracal LC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pulpotomy
Trial: NCT00012311
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00012311
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01141595
Drug: sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
Trial: NCT03528512
Drug: Midazolam and fentanyl
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
Trial: NCT04082000
Drug: BOL-DP-o-04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOL-DP-o-04
Trial: NCT04082000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04418297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT02144415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 x matching placebo capsules
Trial: NCT03537014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo during three experimental sessions
Trial: NCT00677365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same frequency as study drug using the same nebulizer
Trial: NCT00294112
Drug: Prochymal™ adult human mesenchymal stem cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cells in plasmalyte and containing dimethylsulfoxide
Trial: NCT01587001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo three times daily for 8 weeks.
Trial: NCT02173795
Drug: Berodual® MA HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02448732
Drug: ACM-1
RxNorm normalized name: ACMELLA OLERACEA FLOWER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
Trial: NCT02157974
Drug: Byetta 5Mcg Pen Injection
RxNorm normalized name: Byetta 5mcg Pen Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
Trial: NCT02538627
Drug: MM-141
RxNorm normalized name: inositol 141 MG
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MM-141
Trial: NCT01486667
Drug: levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
Trial: NCT03476369
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Premedicated with Fentanyl (at least 25mcg by IV)
Trial: NCT04102111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral tablets of matching placebo twice daily.
Trial: NCT01052298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
Trial: NCT00171392
Drug: Enteric-coated mycophenolate sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03958396
Drug: Remifentanil Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
Trial: NCT00864331
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy given alone
Trial: NCT00887198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 placebo tablets per day taken orally.
Trial: NCT00280761
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
Trial: NCT01462708
Drug: [18F]MK-9470
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not \>10% of 10 mCi limit)of \[18F\]MK-9470, followed by PET imaging.
Trial: NCT00091832
Drug: IV Bisphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
Trial: NCT02258074
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01986998
Drug: Methylprednisolone 1250 mg/24h x3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
Trial: NCT02258074
Drug: Placebo (for Nicotinamide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
Trial: NCT03325881
Drug: SHP465
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP465 capsule 6.25 mg orally once daily for 4 weeks
Trial: NCT03325881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to SHP465 capsule orally once daily for 4 weeks
Trial: NCT02794584
Drug: sufentanil anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Trial: NCT01459250
Drug: AGO178C
FDA approved: no
EMA approved: no
PMDA approved: no